1. Home
  2. BMRN vs FRHC Comparison

BMRN vs FRHC Comparison

Compare BMRN & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMRN
  • FRHC
  • Stock Information
  • Founded
  • BMRN 1996
  • FRHC N/A
  • Country
  • BMRN United States
  • FRHC United States
  • Employees
  • BMRN N/A
  • FRHC N/A
  • Industry
  • BMRN Biotechnology: Pharmaceutical Preparations
  • FRHC Investment Bankers/Brokers/Service
  • Sector
  • BMRN Health Care
  • FRHC Finance
  • Exchange
  • BMRN Nasdaq
  • FRHC Nasdaq
  • Market Cap
  • BMRN 10.5B
  • FRHC 8.7B
  • IPO Year
  • BMRN 1999
  • FRHC N/A
  • Fundamental
  • Price
  • BMRN $54.29
  • FRHC $137.22
  • Analyst Decision
  • BMRN Buy
  • FRHC
  • Analyst Count
  • BMRN 19
  • FRHC 0
  • Target Price
  • BMRN $90.26
  • FRHC N/A
  • AVG Volume (30 Days)
  • BMRN 2.8M
  • FRHC 106.1K
  • Earning Date
  • BMRN 10-27-2025
  • FRHC 11-07-2025
  • Dividend Yield
  • BMRN N/A
  • FRHC N/A
  • EPS Growth
  • BMRN 59.53
  • FRHC N/A
  • EPS
  • BMRN 2.68
  • FRHC 0.08
  • Revenue
  • BMRN $3,094,001,000.00
  • FRHC $1,563,510,000.00
  • Revenue This Year
  • BMRN $13.32
  • FRHC N/A
  • Revenue Next Year
  • BMRN $7.51
  • FRHC N/A
  • P/E Ratio
  • BMRN $20.20
  • FRHC $1,789.08
  • Revenue Growth
  • BMRN 12.39
  • FRHC 16.04
  • 52 Week Low
  • BMRN $50.76
  • FRHC $111.85
  • 52 Week High
  • BMRN $73.51
  • FRHC $194.01
  • Technical
  • Relative Strength Index (RSI)
  • BMRN 53.35
  • FRHC 37.56
  • Support Level
  • BMRN $53.67
  • FRHC $134.00
  • Resistance Level
  • BMRN $55.34
  • FRHC $143.36
  • Average True Range (ATR)
  • BMRN 1.49
  • FRHC 6.25
  • MACD
  • BMRN 0.28
  • FRHC -0.19
  • Stochastic Oscillator
  • BMRN 78.60
  • FRHC 30.99

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

About FRHC Freedom Holding Corp.

Freedom Holding Corp is a holding company with its subsidiary it is engaged in securities brokerage, securities dealing for customers and account, market-making activities, investment research, investment counseling, investment banking services, retail and commercial banking, insurance products, payment services, and information processing services. It acts as a professional participant through its subsidiaries on the Kazakhstan Stock Exchange (KASE), Moscow Exchange (MOEX), Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, the Uzbek Republican Currency Exchange (UZCE), and the Republican Stock Exchange of Tashkent (UZSE). Its segments are Brokerage, Banking, Insurance, and Others.

Share on Social Networks: